We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

168 hedge funds and large institutions have $3.08B invested in Rhythm Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 42 increasing their positions, 63 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,509% more call options, than puts

Call options by funds: $50M | Put options by funds: $3.11M

132% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 19

97% more capital invested

Capital invested by funds: $1.56B → $3.08B (+$1.51B)

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

17% more funds holding

Funds holding: 143 → 168 (+25)

6.5% less ownership

Funds ownership: 119.74% → 113.24% (-6.5%)

33% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 63

Holders
168
Holders Change
+25
Holders Change %
+17.48%
% of All Funds
2.45%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.15%
New
44
Increased
42
Reduced
63
Closed
19
Calls
$50M
Puts
$3.11M
Net Calls
+$46.9M
Net Calls Change
+$37.3M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$55.9M
2
Pictet Asset Management
Pictet Asset Management
Switzerland
+$36.7M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.4M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
+$10.8M
5
DCM
Driehaus Capital Management
Illinois
+$10.2M

Top Sellers

Rank Fund Capital Flow
1
Alkeon Capital Management
Alkeon Capital Management
New York
-$39.5M
2
PCH
Polar Capital Holdings
United Kingdom
-$23.7M
3
VA
VR Adviser
New York
-$18.7M
4
CC
Commodore Capital
New York
-$16.6M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
76
Wells Fargo
California
$1.83M -$440K -13,950 -26%
Manulife (Manufacturers Life Insurance)
77
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.8M +$602K +19,075 +95%
TD Asset Management
78
TD Asset Management
Ontario, Canada
$1.74M +$1.19M +37,800 New
State of Wisconsin Investment Board
79
State of Wisconsin Investment Board
Wisconsin
$1.72M -$38.6K -1,223 -3%
Millennium Management
80
Millennium Management
New York
$1.6M -$124K -3,941 -10%
Comerica Bank
81
Comerica Bank
Texas
$1.57M -$367K -11,620 -25%
New York State Common Retirement Fund
82
New York State Common Retirement Fund
New York
$1.51M +$386K +12,233 +59%
BG
83
Bellevue Group
Switzerland
$1.51M -$1.28M -40,431 -55%
Susquehanna International Group
84
Susquehanna International Group
Pennsylvania
$1.48M +$56K +1,776 +6%
Stifel Financial
85
Stifel Financial
Missouri
$1.41M -$485K -15,365 -33%
Mirae Asset Global Investments
86
Mirae Asset Global Investments
South Korea
$1.35M -$28K -889 -3%
AG
87
Algert Global
California
$1.32M -$145K -4,610 -14%
MIM
88
MetLife Investment Management
New Jersey
$1.25M – – –
Deutsche Bank
89
Deutsche Bank
Germany
$1.24M -$12.7K -404 -1%
VF
90
Virtu Financial
New York
$1.22M +$836K +26,501 New
AIG
91
American International Group
New York
$1.17M -$3.25K -103 -0.4%
AI
92
Atom Investors
Texas
$1.15M +$175K +5,545 +29%
Ameriprise
93
Ameriprise
Minnesota
$964K -$31.5K -1,000 -5%
PA
94
Profund Advisors
Maryland
$942K -$231K -7,327 -26%
FT
95
Fiduciary Trust
Massachusetts
$919K – – –
Ensign Peak Advisors
96
Ensign Peak Advisors
Utah
$853K – – –
GAM
97
Gotham Asset Management
New York
$849K +$131K +4,154 +29%
PCM
98
Prelude Capital Management
New York
$800K +$31.5K +1,000 +6%
Royal Bank of Canada
99
Royal Bank of Canada
Ontario, Canada
$743K +$129K +4,089 +34%
Squarepoint
100
Squarepoint
New York
$706K +$484K +15,350 New
2 3
4
5 6

RYTM Hedge Fund Activity: Q4 2023 in Review

168 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2023, worth a combined $3.08B — up 97% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RYTM positions and 19 closed out — a net gain of 25 holders — while 42 added to existing stakes and 63 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $55.9M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $39.5M sold.

  • 168 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2023, up from 143 in Q3 2023.
  • Funds reported $3.08B of Rhythm Pharmaceuticals stock for Q4 2023, up 97% quarter-over-quarter.
  • 44 funds opened new Rhythm Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +25 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q4 2023 was Perceptive Advisors, an estimated $55.9M added.
  • The largest Rhythm Pharmaceuticals seller in Q4 2023 was Alkeon Capital Management, an estimated $39.5M sold.

Based on aggregated 13F filings for Q4 2023.